FDA approves powerful HIV drug that nearly eliminated spread in clinical trials
a year ago
- #HIV prevention
- #public health
- #medical breakthrough
- FDA approves new HIV-prevention drug Yeztugo (lenacapavir), which is highly effective with injections every six months.
- Yeztugo shows 89-96% lower HIV rates compared to Truvada in clinical trials, with no infections among cisgender women in sub-Saharan Africa.
- The drug is the first in a new class of antiretrovirals, blocking HIV from infecting immune cells and requiring only biannual injections.
- Despite its effectiveness, Yeztugo faces hurdles like high cost ($14,109 per injection), potential insurance coverage issues, and political challenges.
- PrEP usage has risen but remains low among Black and Latino gay men, highlighting disparities in HIV prevention.
- Trump administration budget cuts threaten HIV prevention efforts, including funding for CDC and NIH research.
- Gilead offers financial assistance programs to help cover Yeztugo costs for insured and uninsured patients.
- Telehealth companies like Mistr plan to offer Yeztugo immediately, partnering with clinics to provide access.